Key result
Nisoldipine-CC fails to improve exercise time vs placebo but prolongs time to ST deviation.
Why the study?
The study was conducted to evaluate the effect of nisoldipine coat-core on exercise capacity in patients after myocardial infarction.
Does nisoldipine-CC improve exercise time in patients 7-10 days post-myocardial infarction with LVEF 25-50% and no heart failure?
RCT (n=542)
Double-blind
randomized
Yes
Does nisoldipine-CC improve exercise time in patients 7-10 days post-myocardial infarction with LVEF 25-50% and no heart failure?
In post-MI patients with asymptomatic LV dysfunction, nisoldipine-CC did not improve exercise time but improved diastolic left ventricular function and delayed exercise-induced ischemia.
Answers are grounded in this paper and cite their sources.
Nisoldipine-CC failed to improve post-MI exercise capacity; leaves open potential diastolic or ischemic benefits for targeted trials.
AIMS: A multicentre, double-blind, placebo-controlled trial was conducted in 542 patients, randomized 7-10 days after myocardial infarction, to study the effect of nisoldipine coat-core (nisoldipine-CC) on exercise after 6 months. Secondary endpoints included exercise-induced ischaemia, left ventricular function measured by Doppler echocardiography, adverse cardiac events and clinical outcome. METHODS AND RESULTS: Patients had reduced left ventricular ejection fraction between 25 and 50%, but no heart failure. Exercise time was not different in the two groups. Nisoldipine-CC prolonged time to 1 mm ST deviation (P = 0.03). There was an effect of nisoldipine-CC of +3.6 cm.s-1 on early peak velocity (P = 0.01) and of -6.2 ms on isovolumic relaxation time (P = 0.005), but no effects on left ventricular volumes or ejection fraction. There was a trend towards reduced mortality (one death in the nisoldipine-CC group vs seven in the placebo group. P < 0.07) and the combined end-point of mortality and cardiac events (P = 0.09). Peripheral oedema occurred in 49 patients assigned to nisoldipine-CC and two assigned to placebo (P < 0.001). There were no differences in non-cardiac events. CONCLUSIONS: Nisoldipine-CC did not improve exercise time but increased time to 1 mm ST deviation, and improved diastolic left ventricular function. It is safe and well tolerated in post-infarction patients with impaired left ventricular function.
No takes yet. Share an insight, caveat, or question.
A 1997 study conducted an RCT in myocardial infarction (n=542). Nisoldipine coat-core vs. Placebo was evaluated on Exercise time at 6 months. Nisoldipine-CC did not improve exercise time compared to placebo, but prolonged time to 1 mm ST deviation and improved early peak velocity by 3.6 cm/s.
Synapse has enriched 10 related papers. Consider them for comparative context: